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Although the etiology of sarcoidosis is unknown, genetic susceptibility has been demonstrated.
Granuloma formation is a key feature in the pathophysiology of sarcoidosis and Crohn’s
Disease, raising the possibility that these diseases share common pathogenetic pathways. An
association between sarcoidosis and the protein “CD14”, a molecule that is part of the lipo-
polysaccharide (LPS) cell surface receptor complex, has been suggested.
In the current study we evaluated the CD14 gene promoter 159 C/ T polymorphic site and
soluble CD14 levels in a cohort of 74 sarcoidosis patients compared to 85 healthy controls. We
further sought to identify correlations between clinical phenotype, specific genotypes and
soluble CD14 levels.
We found the TT genotype to be more prevalent in the sarcoidosis patient group than in
controls (pZ 0.03). Serum levels of soluble CD14 were higher in the sarcoidosis patients
(pZ 0.001). Within the patient cohort, CC homozygous patients presented at an older age with
milder disease as assessed with the SAC score, longer time to diagnosis, and less impairment of
pulmonary function tests.
Our study suggests a role of CD14 in the pathogenesis of sarcoidosis, and a clinical
phenotype-genotype association. Further mechanistic and epidemiologic studies are needed
in order to establish the specific role of CD14 in the etiology, pathogenesis and clinical pheno-
type of sarcoidosis.
ª 2010 Elsevier Ltd. All rights reserved.50 5172444.
ah.org.il (Z.G. Fridlender).
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Sarcoidosis is a systemic inflammatory granulomatous
disease that can involve almost every organ system in the
body. The course of the disease is highly variable and
unpredictable, ranging from a mild self-limiting form to
a severe debilitating and even fatal disease.1,2 The etiology
of sarcoidosis is unknown, however, genetic susceptibility
has been demonstrated, with evidence of familial aggre-
gation and racial variance in disease incidence.3e6
The characteristic pathological feature of sarcoidosis is
the non-caseating granuloma. The mechanism of granuloma
formation involves the activation of Th1 helper cells by
Antigen Presenting Cells (APC’s), and secretion of monocyte
chemotactic cytokines.1e3 Formation of granulomas is also
an essential process in the pathophysiology of Crohn’s
Disease, raising the possibility that these two diseases share
common pathogenetic pathways.3,7
CD14 is a myeloid-monocytic marker antigen, expressed
as either a 55 kDa membrane bound protein (mCD14), or as
a 48 kDa soluble plasma protein (sCD14).8 It acts as part of
the lipopolysaccharide (LPS) cell surface receptor complex.
CD14 binding leads to the activation of NFkB, followed by
up-regulation of inflammatory mediators.8 Despite signifi-
cant progress in understanding the origin of soluble CD14
(sCD14), its physiological function remains largely
unknown.9 On one hand, sCD14 has been shown to induce
an inflammatory response in non-myeloid cells lacking the
membrane bound form of the protein.10 In contrast, sCD14
has been shown to have beneficial properties in protection
against LPS-induced endotoxin shock, by acting as
a competitive inhibitor of LPS binding to mCD14.9
The presence of a single nucleotide polymorphism (SNP)
in the proximal promoter of the CD14 gene, 159 C/ T, has
been shown to be related to higher plasma levels of sCD14
(TT), and lower levels of IgE.11 This suggests a role for CD14
in diverting the immune response from a Th2 towards Th1
phenotype.11,12 An increased frequency of the T allele has
been reported in Crohn’s disease.13e15
A possible relationship between Sarcoidosis and CD14
has been suggested previously.16e19 DNA from Gram-
negative bacteria and elevated levels of LPS in Bron-
choalveolar Lavage (BAL) have been observed in sarcoidosis
patients.19 Furthermore, The 159 C/T polymorphism in
the CD14 gene has been shown to increase TNF-a produc-
tion in response to LPS and Gram-positive and Gram-
negative bacteria.20
In the current study we evaluated the CD14 159 C/ T
polymorphic site and determined soluble CD14 levels in
a cohort of 74 sarcoidosis patients and compared these to
a cohort of 85 healthy controls. We further sought to
identify the presence of correlations between clinical
phenotype, specific genotypes (TT, CT, CC) and soluble
CD14 levels.
Materials and methods
Study population
Patients were recruited from a 12-year database
(1995e2006), of patients diagnosed with Sarcoidosis by thepathology service at the Hadassah Medical Center Jer-
usalem, Israel and from patients attending a large outpa-
tient pulmonary clinic in Jerusalem. Charts of patients with
a biopsy from lung, lymph nodes or skin compatible with
sarcoidosis (non-caseating granulomata), were evaluated.
Patients with a compatible clinical picture as determined
by symptoms, laboratory abnormalities and/or imaging and
without another identified cause of granulomatous disease
were included in the initial cohort. Clinical and demo-
graphic information was gathered from a patient ques-
tionnaire, hospital medical records and a treating physician
questionnaire. Where we found discrepancies between the
data reported by the patient and that found in physician’s
questionnaires or in medical records, we used the latter.
Blood samples were obtained from patients for DNA anal-
ysis. A cohort of healthy subjects with no significant
medical background, and no regular medications was
recruited as a control group (nZ 85). All participants
signed an Informed Consent Form and the study was
approved by the institutional Ethics Committee.
Assesement of disease extent and severity
Duration of symptoms prior to diagnosis was evaluated from
patient reports and documented medical records. Cases in
which duration of symptoms could not be accurately eval-
uated were excluded from analysis. Determination of which
organ systems were involved in the disease was evaluated
based on patient records and physician questionnaires.
The severity assessment of sarcoidosis was done using
the modified Sarcoidosis Activity (SAC) Score.21 This score
assesses disease severity using the following equation:
ScoreZ11:46þ 3:9Cþ 2:56Nþ 1:56ðISÞ
0:051ðFVC % predictedÞ þ 1:75ðAAÞ
0:054ðFEV1=FVCÞ
where CZ cardiac involvement (0/1), NZ Neurologic
Involvement, ISZ non-steroid immunosuppression (0/1),
AAZ African American.
Evaluation of sCD14 levels
Plasma was separated from the blood samples obtained, and
immediately frozen at 20 C. sCD14 levels in the plasma
were measured using the commercially available CD14 Duo-
Set ELISAdevelopmentKit, according to theprotocol supplied
by the manufacturer (R&D Systems, Minneapolis, MN).
Genotype analysis
Genomic DNA was extracted from anticoagulated whole
blood collected in EDTA from patients and controls. Isola-
tion of DNA was done by phenolechloroform extraction and
alcohol precipitation as previously described.22
The CD14 e159C/ T polymorphism was assessed by
Polymerase Chain Reaction-Restriction Fragment Length
Polymorphism (PCR-RFLP), as previously described.23 PCR
amplification was performed using the following primers:
Forward: 5’GCCTCTGACAGTTTATGTAATC3’.
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The PCR product was then digested by the restriction
enzyme AVAII (New England Biolabs, Ipswich, MA) in 37 C
for 10 h, resolved by electrophoresis on 1.8% Agarose Gel
(SeaKem LE Agarose, Cambrex) and stained with Ethidium
Bromide (Sigma, Israel). The presence of the T allele
creates a restriction site for AVAII, yielding a 144-bp and
353-bp bands, whereas the C allele, which remains uncut,
yields a single 497-bp band.
Lung function tests
For this analysis, we used only lung function tests (LFT) that
were performed at the time of diagnosis when patients
were on no treatment. Patients that did not have available
LFT at the time of diagnosis were excluded from this
analysis. Spirometry was performed using a pneumotacho-
graph-based system. The reference equations and correc-
tions used for the measurements of spirometry, lung
volumes and DLCO were those published by the European
Community for Coal and Steel (ECCS).24 No ethnic correc-
tion factors are used for our patients.
Statistical analysis
Differences in demographic parameters in the study groups,
the frequencies of the polymorphic genotypes and clinical
differences between them were analyzed using the proper
c2-test (either 2 2 or 2 3 according to the question
tested). The difference between sCD14 levels in controls
vs. Sarcoidosis patients, and the comparisons of continuous
parameters (i.e. lung function tests) comparing the CC
genotype to the non-CC genotype were analyzed using
Student’s t-test. To evaluate the level of sCD14 in the
different genotypes, we used ANOVA with appropriate post
hoc testing. p< 0.05 was considered to be statistically
significant.
Results
Study population and patient characteristics
A total of 350 sarcoidosis patients were identified. Of these,
seventy-four patients together with 85 control subjects
were recruited for this study. 32.4% of the patients and
42.8% of the controls were males, 77% of the patients and
82.4% of the controls were of Jewish origin (both differ-
ences - NS). Remaining subjects in both groups were of Arab
origin.
Table 1 presents the clinical data of the sarcoidosis
patients. The average age at diagnosis was 52.7 11.5
years. Most patients in this cohort (82%) were diagnosed by
endobronchial and/or transbronchial biopsies performed
via fiberoptic bronchoscopy. In only one patient a surgical
lung biopsy was required for diagnosis. The most common
symptoms at presentation were cough (60%) and dyspnea
(66%) and 77% of the patients had at-least one of these two
respiratory symptoms. An additional 12% of patients, who
did not have respiratory symptoms, were found to havepulmonary involvement on biopsy or imaging studies.
Thoracic lymph nodes were enlarged in 85% of the patients,
as noted by imaging. Pulmonary parenchymal involvement
was noted in 85% of the patients. Interstitial markings in the
lung parenchyma were reported in 47%, and nodular
patterns in 47%. The majority of the patients (61%) had the
Scadding radiographic score of 2. About half the patients
required treatment with systemic corticosteroids during
the course of their disease and 17.6% received additional
treatment. 8.1% of patients were treated with
methotrexate.
CD14 genotypes in sarcoidosis patients and healthy
subjects
Fig. 1 shows the frequency of the different genotypes of
CD14 in the sarcoidosis patients and the healthy controls.
The distribution of the genotypes was not significantly
different between patients with sarcoidosis and controls.
However, we noted a trend toward more of the sarcoidosis
patients being homozygous for the T allele (genotype TT,
29.7% vs. 20% in controls), and less being homozygous for
the CC allele (Genotype CC, 23% vs. 32%).
sCD14 serum levels
Mean serum levels of sCD14 were 1.9 0.96 mg/ml in the
sarcoidosis patients, and 1.31 0.77 mg/ml in the healthy
control group (pZ 0.001) (Fig. 2). We noted a trend that in
the sarcoidosis patients with sCD14> 1.9 (mean level), the
percentage of patients with the CC genotype was 29.4%
(10/34) compared to 17.5% only (7/40) in the patients with
sCD14 levels below that level (pZ 0.09). We did not find
clear correlation between any specific genotype and sCD14
serum levels in either the patients (Fig. 2b) or healthy
control subjects (data not shown). In order to factor in the
effect of corticosteroid treatment at the time of sCD14
evaluation, we compared the level of sCD14 between
patients that were not treated at all (nZ 24), and patients
that were treated with corticosteroids at any time
(nZ 37). The level of sCD14 was 1.87 0.15 without
treatment, and 1.82 0.18 with corticosteroids (NS). The
level of sCD14 in sarcoidosis patients that were never
treated was significantly higher than in healthy controls
(p< 0.05).
CD14 alleles and clinical phenotype
In order to evaluate the influence of CD14 genotypes, we
compared the clinical characteristics of the patients
according to different genotypes. Our first impression was
that the patients with the CC phenotype had milder
disease. This premise was supported by assessing the
severity of the disease using the SAC score.21 As can be seen
in Fig. 3, the mean score in the CC homozygous group
(patients lacking the T allele, 17/74, 23% of patients) was
2.19 0.24. This was significantly different than the mean
score in the TT homozygous group (3.44 0.31, p< 0.05),
and from the mean score in the TC heterozygous group
(3.30 0.39, p< 0.05). There was no significant difference
between the TC and the TT groups. Furthermore, similar to
Table 1 Demographic and clinical characteristics of the sarcoidosis patients.
% of patients (n)
Age at diagnosis (years) 52.7 11.5
Gender Male 32.4 (24)
Female 67.6 (50)
Symptoms Dyspnea 59.5 (44)
Cough 66.2 (49)
Any respiratory symptom 77 (57)
Fever 16.2 (12)
Weight loss 16.2 (12)
Arthralgia/arthritis 25.7 (19)
Ocular symptoms 4.1 (3)
Skin 13.5 (10)
Asymptomatic 14.9 (11)
Others 12.2 (9)
Duration of symptoms prior
to diagnosis (nZ 54)
<1 m 15 (8)
1e3 m 38.9 (21)
4e6 m 3.7 (2)
7e12 m 20.4 (11)
>12 m 22.2 (12)
Pathological involvement
shown (granulomata)
Lung 83.8 (62)
Thoracic LN 4.1 (3)
Extra Thoracic LN 4.1 (3)
Liver 2.7 (2)
Bone marrow 1.4 (1)
Skin 2.7 (2)
Others 1.4 (1)
Extent of disease
(Objective and/or subjective)
Pulmonary 89.2 (66)
Thoracic LN 87.8 (65)
Extra-thoracic LN 23 (17)
Parenchymal Disease 20.3 (15)
Ocular 14.9 (11)
Joints 27 (20)
Hypercalcemia/hypercalciuria 5.4 (4)
Skin 14.9 (11)
neurologic 2.7 (2)
Cardiac 2.7 (2)
Others 2.7 (2)
Radiology findings Thoracic LN 85.1 (63)
Interstitial markings 47.3(35)
Nodular opacities 47.3 (35)
Cervical/axillary/supra-clavicular LN 6.8 (5)
Retroperitoneal/mesenteric LN 10.8 (8)
Hepato-splenic involvement 20.3 (15)
Unknown 2.7 (2)
Scadding chest radiographic class 0 2.7 (2)
1 13.5 (10)
2 68.9 (51)
3 8.1 (6)
4 6.8 (5)
Pulmonary function tests
(% of predicted SD)
Total lung capacity (TLC) 92.9 14.5
Functional residual capacity (FRC) 92.8 18
Vital capacity (VC) 92.4 20.6
Residual volume (RV) 106.4 26.3
Forced expiratory volume 1.0 s (FEV1) 85.5 21.6
Forced vital capacity (FVC) 89 19.7
FEV1/FVC 79.1 10.3
DLCO 80.4 18.5
Treatment (tx) Methotrexate 8.11 (6)
Ever Required Steroids 48.6 (36)
Treated e not with steroids/cytotoxics 9.5 (7)
No Tx or unknown 33.8 (25)
Figure 1 Polymorphism in CD14 in patients and healthy
controls e polymorphism of the CD14 promoter site 159C/ T
was assessed in 74 sarcoidosis patients and 85 healthy controls
by polymerase chain reaction-restriction Fragment Length
Polymorphism (PCR-RFLP). The percentage of patients and
controls with each of the three possible combinations (CC, CT
and TT) was calculated, and the prevalence of each genotype
was compared in patients and controls.
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of the T allele (e.g. TC and TT) is associated with increased
susceptibility for developing sarcoidosis,18 and developing
Crohn’s disease,13e15 which has some pathophysiological
similarities to sarcoidosis. Based on these findings, we
evaluated the clinical differences between the CC patient
group and the rest of the patients. The SAC score in all non-
CC genotypes was 3.39 0.24, significantly higher than in
the patients with the CC genotype (p< 0.01). There was
a greater predominance of females (82.4% vs. 63.2%,
pZ 0.04) and the age at diagnosis was significantly higher
in the CC group (57.8 8.3 vs. 51.1 12.9, pZ 0.006). CC
patients were less likely to present with acute disease.
From the patients in whom relevant information prior to
diagnosis could be found, 0/15 of CC patients were
diagnosed within one month of onset of symptoms vs. 8/39
(21%) in the other genotypes (pZ 0.049). Pulmonary
function tests (PFTs) at diagnosis were significantly better
in the CC patients. The greatest difference was found in
forced vital capacity (100.6 21.6% of predicted in the CC
patients vs. 85.6 18.1 % in the other patients: (p< 0.04)).
Significant differences between CC and other patients were
also observed for TLC, and FEV1. The percentage ofFigure 2 Soluble CD14 levels ethe level of soluble CD14 in the pla
by ELISA. Panel A compares patients with healthy controls (*p<
Polymorphic CD14 promoter site 159C/ T (CC, CT and TT) in patiepatients with an abnormality in pulmonary function tests
(either Total Lung capacity (TLC)< 80%, Forced Vital
Capacity (FVC)< 80% or Forced Expiratory Volume in 1 sec.
(FEV1)< 70%) was significantly lower in CC patients (17.6%)
as compared to the other patients (42.6%). The major
differences between the patients carrying the allele T and
those who don’t are summarized in Table 2. When
comparing patients with the TT genotype to “non-TT”
patients, the only significant finding was a lower incidence
of ocular involvement with the TT genotype (4.5%) vs. the
other patients (19.2%) (pZ 0.001).
Discussion
Sarcoidosis is an inflammatory disease in which an aberrant
immune response directed against an unknown antigen or
infection in a genetically susceptible host is the most likely
etiological mechanism of disease.3,4 In the current study,
we found an association between genotype at the poly-
morphic site of the CD14 proximal promoter at the e159
site, and both disease prevalence and clinical phenotype in
an Israeli cohort of sarcoidosis patients. We also found that
serum levels of soluble CD14 were significantly higher in
patients compared to controls.
The demographic characteristics of our cohort were
similar to a previous report of sarcoidosis in Israel in terms
of age and gender distribution with a female to male ratio
of 2:1.25 Most of the patients in our cohort were diagnosed
by flexible bronchoscopy and lung biopsy, and in the vast
majority of cases, the lungs and thoracic lymph nodes were
involved in the disease, a finding similar to previous
studies.1,26 As in the previous report from Israel,25 about
half of our patients required treatment with systemic
corticosteroids during the course of their disease, a higher
rate than reported in other parts of the world.26,27
Although the disease entity termed “sarcoidosis” has
been known to modern medicine for a very long period of
time, little is known about the etiology and pathogenesis
of the disease.2 The pathophysiology of sarcoidosis and that
of Crohn’s disease share several similarities such as in the
significant role for the Th1 like immune response in both
diseases.3,7 A major factor leading to Th1 differentiation is
exposure to bacterial pathogens, and specifically, the
Gram-negative endotoxin lipopolysaccharide (LPS).8sma of sarcoidosis patients and healthy controls was evaluated
0.001). Panel B shows the different genotypic groups in the
nts with sarcoidosis. Each dot represents an individual patient.
Figure 3 Polymorphism in CD14 and the SAC score e patients
were evaluated for disease severity using the modified
sarcoidosis activity (SAC) score. This figure shows the individual
scores of the different genotypic groups in the Polymorphic
CD14 promoter site 159C/ T (CC, CT and TT). Each dot
represents an individual patient. (*p< 0.05, and pZ 0.07).
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genesis of Crohn’s Disease.28 An etiological role for bacte-
rial infection in sarcoidosis have been suggested, and
several studies have found correlations between sarcoidosis
and exposure to different bacteria, including common
Gram-negative bacteria such as Moraxella catarhalis and
Hemophilus influenza,19 Mycobacteria,29 Ricketssial species
and propionibacteria.29,30Table 2 Sarcoidosis patients with CC genotype in the e159C/
carrying the T allele (TC or TT).
Age at diagnosis (years)
Gender Male
Female
Symptoms prior to diagnosis< 1 month
Skin involvement
Radiological findings Interstitial markings
Retroperitoneal/mese
Scadding chest radiographic class 0
1
2
3
4
Pulmonary function tests at diagnosis
(% of predicted SD)
Total lung capacity (T
Vital capacity (VC)
Residual volume (RV)
Forced expiratory vol
1.0 s (FEV1)
Forced vital capacity
DLCO
Abnormalities in pulmonary
function tests
FVC< 80%
TLC< 80%
FEV1< 70%
Either 1 of the 3 abovCD14 is the myeloid receptor for LPS and mediates the
interaction between the immune system and Gram-
negative bacteria, leading to the Th1 like immune
response.8,9 The CD14 e159 C/T polymorphism in the gene
promoter has been shown to be relevant in several disease
states including atopic diseases and asthma,11,31 Kawasaki23
and Crohn’s disease.13e15 Only one recent study, performed
in a Greek population, found a correlation between poly-
morphism at the e159 site and the incidence of sarcoidosis.
Similar to the trend we noted, the authors found that the
TT genotype is more frequent in sarcoidosis patients
compared to healthy controls but they found no correlation
between the specific genotypes and disease phenotype.18
Our results, therefore supports the relevance of the
specific CD14 genotype to the prevalence of sarcoidosis,
and further show that this genotype affects the clinical
phenotype of the disease.
Previous studies of CD14 in sarcoidosis patients have
evaluated the presence of the soluble protein in serum and
bronchoalveolar fluid in the patients, and the expression of
the membrane bound protein on the surface of monocytes
derived from these patients.16,17 In two previously pub-
lished small cohorts, it has been shown that sCD14 serum
levels in sarcoidosis patients are higher than in control
subjects.16,17 Striz et al. showed increased levels of sCD14
in thirteen patients with active disease and not in another
nine patients with inactive sarcoidosis.16 In our study, we
did not stratify patients according to disease activity, or
based on the use of immunosuppressant medications at the
time the blood was drawn. However, we did find signifi-
cantly higher levels of sCD14 in sarcoidosis patients
compared to controls in a much larger patient cohort.T polymorphic site of the CD14 gene compared to patients
CC genotype
% (n)
All other
patients % (n)
p-value
57.8 8.3 51.1 12.9 0.006
17.6% (3) 36.8% (21) 0.04
82.4% (14) 63.2% (36)
0 22% (8) 0.048
29.4% (5) 10.5% (6) 0.006
68.7% (11) 42.1% (24) 0.02
nteric LN 0 14.5% (8) 0.09
6. 2% (1) 1.8% (1) NS
0 15.8% (9)
81.3% (13) 66.6% (38)
12.5% (2) 7% (4)
0 8.8 %(5)
LC) 98.9 14.6 91.3 14.2 0.04
104.7 19.8 88.5 19.7 0.02
102.2 25.1 107.3 26.2 NS
ume 95.8 21 82.5 20.9 0.04
(FVC) 100.6 21.6 85.6 18.1 0.04
82.1 19.6 79.8 18.5 NS
12.5 % (2) 24.3 % (17) 0.07
6.7 % (1) 26.1 % (12) 0.09
5.9 % (1) 9.3 % (5) NS
e 17.6 % (3) 42.6 % (23) 0.001
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in sarcoidosis patients that were never treated with corti-
costeroids compared to those that were treated with
corticosteroids at any time (including at the time of blood
draw). This result further supports our assessment that
corticosteroids do not significantly change the level of
sCD14 in sarcoidosis patients. sCD14 could be an acute
phase protein that can be seen with active inflammation
and may not be specific to sarcoidosis. Parallel evaluation
of other acute phase reactants (i.e. CRP or IL-6) would be of
value to help clarify whether the increase in sCD14 can be
attributed directly to the granulomatous process rather
than to non-specific inflammation. Interestingly, the use of
corticosteroids has been actually shown to reduce the level
of sCD14.32 The lack of adjustment to therapy may have
lead to an underestimation of the magnitude of the
difference in sCD14 between sarcoidosis patients and
healthy controls. Our data suggest the possibility that there
may be a cutoff for sCD14 to distinguish between patients
and control subjects, which may be of value in the diagnosis
of Sarcoidosis. This possibility should be further evaluated
by assessing sCD14 levels in patients with other similar
diseases such as tuberculosis and idiopathic pulmonary
fibrosis (IPF), and also by stratifying the patients based on
activity and the use of medications.
The presence of the T allele in the e159 polymorphism
site in the CD14 gene promoter has been previously sug-
gested to be related to higher levels of sCD14.11,12 In our
study, we did not find a clear relationship between any
specific genotype and serum levels in both the patients
and control groups. It is possible that we could not show
a clear association between the genotype and sCD14 levels
due to an insufficient size of the cohort as well as due to
the ethnic variation in our study group. Another factor
could be the fact that we did not match for disease
activity or the medications taken at the time of trial
recruitment and blood draw. It is possible however, that
polymorphism in the CD14 gene does not affect the level of
soluble CD14 but does have an effect on the membrane
bound form of CD14.
Attempts to correlate genotype with disease phenotype
in our patient cohort suggest that differences may exist. We
found that patients with a CC genotype may have a milder
more indolent form of disease, however such analyses may
be confounded by differences in ethnic and geographical
variables and much larger multinational analyses are
required to definitively evaluate genotypeephenotype
correlations.
In conclusion, our study provides several lines of
evidence connecting CD14 and sarcoidosis and suggests
a role of CD14 in the pathogenesis of the disease. CD14 has
an important function in antigen presentation to the cell.12
It is possible that gene polymorphism affects the process of
antigen presentation and immune function in sarcoidosis,
although further mechanistic studies are needed in order to
establish the specific role of CD14 in the etiology and
pathogenesis of sarcoidosis.
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